Windlas Biotech Limited (NSE:WINDLAS) — Market Cap & Net Worth
Market Cap & Net Worth: Windlas Biotech Limited (WINDLAS)
Windlas Biotech Limited (NSE:WINDLAS) has a market capitalization of $250.31 Million (Rs23.15 Billion) as of September 17, 2026. Listed on the NSE stock exchange, this India-based company holds position #15731 globally and #794 in its home market, demonstrating a -2.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Windlas Biotech Limited's stock price Rs1098.15 by its total outstanding shares 21077239 (21.08 Million). Also see balance sheet size of Windlas Biotech Limited for a full breakdown of the balance sheet.
Windlas Biotech Limited Market Cap History: 2021 to 2026
Windlas Biotech Limited's market capitalization history from 2021 to 2026. Data shows growth from $60.96 Million to $250.31 Million (22.30% CAGR). Also see cash flow conversion of Windlas Biotech Limited for how efficiently the company converts equity into cash flow.
Windlas Biotech Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Windlas Biotech Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Windlas Biotech Limited stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.02x
Windlas Biotech Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.30x
Windlas Biotech Limited's market cap is 0.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $60.96 Million | $4.27 Billion | $158.32 Million | 0.01x | 0.39x |
| 2022 | $56.07 Million | $4.63 Billion | $380.89 Million | 0.01x | 0.15x |
| 2023 | $97.12 Million | $5.11 Billion | $426.26 Million | 0.02x | 0.23x |
| 2024 | $237.32 Million | $6.29 Billion | $581.87 Million | 0.04x | 0.41x |
| 2025 | $181.23 Million | $7.60 Billion | $609.94 Million | 0.02x | 0.30x |
Competitor Companies of WINDLAS by Market Capitalization
Companies near Windlas Biotech Limited in the global market cap rankings as of September 17, 2026. Review WINDLAS intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Windlas Biotech Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Windlas Biotech Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Windlas Biotech Limited's market cap moved from $60.96 Million to $ 250.31 Million, with a yearly change of 22.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs250.31 Million | +38.12% |
| 2025 | Rs181.23 Million | -23.64% |
| 2024 | Rs237.32 Million | +144.35% |
| 2023 | Rs97.12 Million | +73.21% |
| 2022 | Rs56.07 Million | -8.02% |
| 2021 | Rs60.96 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Windlas Biotech Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $250.31 Million USD |
| MoneyControl | $250.31 Million USD |
| MarketWatch | $250.31 Million USD |
| marketcap.company | $250.31 Million USD |
| Reuters | $250.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more